Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adult Males of a DNA Plasmid Vaccine for HS Avian Influenza (VGX-3400) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP)

NCT01184976 is registered in ClinicalTrials.gov with GeneOne Life Science, Inc. as lead sponsor.

NCT NCT01184976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01184976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adult Males of a DNA Plasmid Vaccine for HS Avian Influenza (VGX-3400) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP)
Lead sponsor
GeneOne Life Science, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2010
Completion date
April 30, 2012
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy